These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32629127)

  • 21. Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Sourianarayanane A; Talluri J; Humar A; McCullough AJ
    Eur J Gastroenterol Hepatol; 2017 May; 29(5):516-523. PubMed ID: 28079667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.
    Noureddin M; Goodman Z; Tai D; Chng ELK; Ren Y; Boudes P; Shlevin H; Garcia-Tsao G; Harrison SA; Chalasani NP
    Aliment Pharmacol Ther; 2023 Feb; 57(4):409-417. PubMed ID: 36647687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
    Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
    Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.
    Yilmaz Y; Eren F
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
    Gawrieh S; Harlow KE; Pike F; Yates KP; Wilson LA; Cummings OW; Rosenberg WM; Chalasani N; Molleston JP
    J Pediatr; 2021 Dec; 239():161-167.e5. PubMed ID: 34400208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N; Feldstein AE
    Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
    Johnson AL; Hayward KL; Patel P; Horsfall LU; Cheah AEZ; Irvine KM; Russell AW; Stuart KA; Williams S; Hartel G; Valery PC; Powell EE
    Hepatol Commun; 2022 Apr; 6(4):728-739. PubMed ID: 34783191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
    J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
    Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
    Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
    J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
    Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
    Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.